Efficacy of Plerixafor for Peripheral Stem Cell Mobilisation in Autologous Transplantation: A Single Centre Study

Plerixafor\r\nis a stem cell mobilising agent, and when administered along with G-CSF has\r\nbeen shown to improve CD34+ stem cell collections in lymphoma and multiple\r\nmyeloma patients compared to G-CSF alone. Patients who failed to mobilize 6 cells/kg on Day 1 collection received Plerixafor and G CSF for\r\nfurther collections. Study population was divided into two groups as plerixafor\r\nyes (PY) who are poor mobilizers and Plerixafor No (PN) who are good\r\nmobilizers. Out of 49 patients, 28 patients were in PY group and 21 patients in\r\nPN group. Median value of apheresis CD34 of day 1 was 1.75 (range 0.258 to\r\n8.52) in PY group and 2.63 (range 1.06 to 6.29) in PN group and that of day 2\r\nwas 3.845 (range 0.317 to 13.89) in PY group and 3.18 (range 0.88 to 6.348) in\r\nPN group. Median value of total apheresis CD34 was 8.10 (range 4.33 to 18.66)\r\nin PY group and 7.58 (range 4.06 to 9.8) in PN group. Median day of neutrophil\r\nengraftment was 11.5 (range 9 - 22) in PY group and 11 (range 9 - 36) in PN\r\ngroup whereas median day of platelet engraftment was 14 (range 9 - 98) in PY\r\ngroup and 13 (range 11 - 98) in PN group. It can be concluded that the use of\r\nplerixafor not only enabled poor mobilizers of Lymphoma and Multiple Myeloma to\r\ncollect adequate stem cells to proceed to ASCT, but also had early neutrophil\r\nand platelet engraftment which was comparable with good mobilizers.